Kronos and Genentech ink $20M cancer discovery pact

Drew Armstrong

Executive Editor

Kronos Bio and Roche’s Genentech announced a drug discovery deal to hunt for and develop small molecule drugs aimed at transcription factors that can drive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Kronos and Genentech ink $20M cancer discovery pact

Drew Armstrong

Executive Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Kro­nos and Genen­tech ink $20M can­cer dis­cov­ery pact

Executive Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Kronos and Genentech ink $20M cancer discovery pact